ArticleBiosensors2025
An Accumulation Pretreatment-Free POCT Biochip for Visual and Sensitive ABO/Rh Blood Cell Typing.
Article in Biosensors, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Rapid blood type detection in point-of-care testing (POCT) scenarios is crucial for various clinical treatments. In this study, we present a sensitive, cost-effective, and straightforward biosensing approach for visual blood typing that notably simplifies the procedure by eliminating any need for blood sample pretreatment. Our technique achieves this by directly trapping and accumulating red blood cell (RBC) clusters within a photolithography-based microfluidic chip, thereby bypassing complex preprocessing. By employing an antigen-antibody assay involving isoagglutinins A, B, and/or D on the RBC surface and their corresponding antibodies, we effectively determine blood types. When antibodies are present, the corresponding RBCs bind to the antibody-conjugated RBC clusters, which are subsequently trapped within the microfluidic accumulation chip, resulting in the formation of a visible bar. The blood group can then be readily identified by observing this visual bar with the naked eye or under microscopy. Notably, we integrate two continuous mixing units (Z and S) at the entrance of the biochip to improve mixing efficiency and accelerate the antigen-antibody interaction. This method demonstrates high selectivity, accuracy, and stability across various clinical blood samples. Moreover, the sensor operates with minimal sample volume (as low as 10 μL) and delivers results within 5 min. The fabrication cost of the PDMS-based biochip is approximately $0.2 per chip, and the limit of detection (LOD) is determined to be 3 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.